Healthy human gut harbors more than 300 species of microorganisms. These are: bifidobacteria, lactobacteria, non-pathogenic intestinal rods and many others. Containments of intestinal microflora is individual and its formation begins during first days of life.
Particular bacterial combination is called as “microflora”, and any imbalance in its composition is called as “dysbacteriosis”. This term doesn’t concern bacterial quantitative and qualitative change only, but also it encompasses clinical and laboratory syndrome which develops under various clinical situations and disorders. Reduction in bifido- and lactobacteria contributes to growth and colonization of gut by exogenous pathogenic organisms that is critical in the formation of dysbacteriosis.
Dysbacteriosis mainly develops after treatment of acute intestinal infections with antibacterial medications (Antibiotics, Sulfonamides) which destroy not only pathogenic organisms but also normal microflora. Development of dysbacteriosis is also contributed by allergies, GI tract disorders (atrophic gastritis, pancreatic and liver diseases, gastric and small intestinal resections, deranged peristalsis, large bowel stasis), stress, non-prudent diet, particular medications, increased radiation, endocrine problems, kidney disorders, malignancies and etc.
It is important to mention that Intestinal dysbacteriosis is always secondary and revealing the causative reason and its cessation is crucial.
Dysbacteriosis may have marked clinical manifestations (decompensate form) or hidden insidious form (compensated one). Decompensated form is characterized by diarrhea and constipation, often accompanied by immune system derangement (frequent infectious diseases and etc).
Modern method of treatment is correction of deranged microflora by medications that contain live organisms (Probiotics), that have positive influence on gut biogenesis.
These so called Probiotics are live microorganisms by general term and they cause normalization of intestinal flora. Modern Probiotoics have ability to resist acid media, attach to intestinal epithelium and produce anti-microbial substances.
Among these medications Lacidofil-WM (World Medicine, England) is marked by its high efficiency. It has marked antagonistic action against pathogenic organisms, contributes formation of lactose from carbohydrates, fats and proteins, participates in the metabolism of bile acids, in the synthesis of vitamins K and B, contributes to absorption of Vitamin D, Ca and Fe. It has marked immune stimulating and anti-inflammatory actions - decreasing inflammatory cytokine IL-8 secretion and stimulating IL-6 synthesis, it increases cellular immunity and so on.
Apart from some other probiotics Lacidofil-WM has priorities – it is safe in any age-group patients, doesn’t contain pathogenic strains and contributes to maintenance of normal gut flora during treatment with chemotherapeutic drugs.
Indications for Lacidofil-WM are wide and it is easy to use. Its safety and high efficiency contributes its usefulness in rheumatology practice.
In rheumatology patient treatment is mainly by immunosuppressive drugs and antibiotics, that contributes to the development of dysbacteriosis and immunodeficiency.
Long term experience showed that in such cases probiotic Lacidofil-WM is especially beneficial and safe even in severe cases of rheumatologic diseases despite patient age and immune status, because it doesn’t contain pathogenic strains. It improves patient immune status and maintains therapeutic effects for a long period after intake (colonization period of 15-20 days) and marked anti-inflammatory effects.
Use of Lacidofil-WM in rheumatology practice contributes to efficiency of main traditional treatment regimen and lowers rate of infectious complications.